Drugmaker Shire backs new $53.6-bn AbbVie takeover bid (Update)

July 14, 2014 by Roland Jackson

Shire Pharmaceuticals on Monday backed a revised $53.6-billion takeover from US giant AbbVie, reversing its opposition to a deal, and added it was in "detailed discussions" over terms.

AbbVie's latest cash-and-stock proposal for Shire was worth £53.20 per share, valuing the company at the equivalent of £31.35 billion or 39.5 billion euros ($53.8 billion), Shire said in a statement.

The US group's previous offer, pitched only last week, was at £51.15 per share or $51.6 billion.

Shire shareholders are to get £24.44 in cash and 0.8960 shares of new AbbVie per Shire share, and own 25 percent of the combined company, under the new proposal received on Sunday.

'Willing to recommend' bid

"The board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the revised proposal to Shire shareholders subject to satisfactory resolution of the other terms of the offer," Shire said Monday.

"Accordingly, the board is in detailed discussions with AbbVie in relation to these terms," added the group, which is listed in London and New York but based in Dublin.

Shire, which is a specialist in drugs for the treatment of attention-deficit disorder, had previously rejected offers from AbbVie as undervaluing the company's prospects.

It also provides treatments in areas such as rare diseases and neuroscience and is developing products in other therapeutic areas.

Shire had also previously highlighted concerns over AbbVie's plans to make Britain its home base for tax purposes.

The latest proposal remains subject to preconditions set by AbbVie on July 8, including due diligence and the recommendation of the board.

Shire added however that there was no certainty that any firm offer would be made, while a further update would be made when appropriate.

AbbVie, which is listed in New York and was spun off from Abbott Laboratories in January 2013, had been repeatedly rejected by Shire since an initial proposal on May 6 worth £39.50 per share .

The US group, known for the anti-inflammatory drug Humira, has until July 18 to make a formal bid for Shire under British takeover rules.

Shares under bid price

London investors appeared uncertain that the deal would go ahead however, as Shire's share price languished underneath the bid price.

It shares nonetheless gained 2.63 percent to stand at £49.98 pence in late morning deals on London's FTSE 100 index of leading companies, which was up 0.65 percent at 6,733.35 points.

"Shire Pharmaceuticals are trading higher but cautiously below the proposed offer price suggesting investor nerves that the deal may not go ahead despite board approval," noted Mike McCudden, head of derivatives at stockbroker Interactive Investor.

The pharmaceuticals sector has seen a raft of multi-billion-dollar deals in recent months, with US companies looking to Europe as a way to reduce their tax liabilities.

In late May, Anglo-Swedish group AstraZeneca fought off a $117-billion takeover bid from US giant Pfizer, amid worries over British jobs and research capability.

There were also accusations that the tie-up was a cynical ploy by Pfizer to avoid paying tax on profits if they were sent to the United States. The US group had also proposed to switch its tax base to Britain from the United States.

Explore further: AbbVie raises its bid for Shire by about 11 pct (Update)

Related Stories

AbbVie raises its bid for Shire by about 11 pct (Update)

July 8, 2014
U.S. drugmaker AbbVie has boosted its offer for Shire by 11 percent to about $51.3 billion, hoping it will be enough to pique the interest of its British counterpart.

Takeover target Shire promises strong growth

June 23, 2014
Takeover target Shire on Monday highlighted its potential as a standalone drugmaker, offering investors a rosy projection of its earnings potential that it believes is not reflected in the acquisition proposal made by U.S.-based ...

AbbVie cites tax break as a Shire deal motivator

June 25, 2014
U.S. drugmaker AbbVie sees a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well.

Shire buys ViroPharma in $4.2 billion deal (Update)

November 11, 2013
The drugmaker Shire PLC plans to strengthen its rare disease treatment portfolio by spending $4.2 billion in cash to buy the biopharmaceutical company ViroPharma Inc.

Valeant launches hostile $53B bid for Allergan

June 18, 2014
Valeant Pharmaceuticals said Wednesday it has launched a tender offer for Allergan, the maker of Botox, taking its hostile bid directly to shareholders.

Irish biotech firm Elan rejects new Royalty bid

June 10, 2013
Irish biotechnology company Elan rejected on Monday the latest takeover bid from US group Royalty Pharma worth about $7.9 billion (6.0 billion euros).

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.